J. Lipid Res.
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
 QUICK SEARCH:   [advanced]


     


A more recent version of this article appeared on May 1, 2004

Papers In Press, published online ahead of print March 1, 2004
J. Lipid Res., doi:10.1194/jlr.M300487-JLR200
This Article
Right arrow Full Text (Accepted Manuscript)
Right arrow All Versions of this Article:
M300487-JLR200v1
45/5/805    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lie, J.
Right arrow Articles by van Tol, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lie, J.
Right arrow Articles by van Tol, A.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Submitted on December 1, 2003
Revised on February 3, 2004
Accepted on February 19, 2004

Elevation of plasma phospholipid transfer protein increases the risk of atherosclerosis in spite of lowering apolipoprotein B containing lipoproteins

Jessica Lie, Rini de Crom, Teus van Gent, Rien van Haperen, Leo Scheek, Farah Sadeghi-Niaraki, and Arie van Tol

Cell Biology & Genetics, Erasmus University Medical Center, Rotterdam 3015 GD

Corresponding Author: m.decrom{at}erasmusmc.nl

Plasma phospholipid transfer protein (PLTP) transfers phospholipids between lipoproteins and mediates HDL-conversion. PLTP overexpressing mice have increased atherosclerosis. However, mice do not express cholesteryl ester transfer protein (CETP), which is involved in the same metabolic pathways as PLTP. Therefore, we studied atherosclerosis in heterozygous LDL-receptor deficient (LDLR+/-) mice expressing both human CETP and human PLTP. We used 2 transgenic lines with moderately and highly elevated plasma PLTP activity. In LDLR+/-/huCETPtg mice, cholesterol is present in both LDL and HDL. Both are decreased in LDLR+/-/huCETPtg/huPLTPtg mice (>50%). Atherogenic diet resulted in high levels of VLDL+LDL cholesterol. PLTP expression caused a strong PLTP-dose dependent decrease in VLDL+LDL cholesterol (–26% and –69%) and a decrease in HDL-cholesterol (–70%). Surprisingly, atherosclerosis was increased in PLTP overexpressing lines (1.9x and 4.4x, respectively), indicating that the adverse effect of the reduction in plasma HDL outweighs the beneficial effect of the reduction in apolipoprotein B containing lipoproteins. The activities of the anti-atherogenic enzymes, paraoxonase (PON) and platelet activating factor acetyl hydrolase (PAF-AH), were both PLTP dose dependently reduced (about -33 and –65%). We conclude that expression of PLTP in this animal model results in increased atherosclerosis in spite of reduced apolipoprotein B containing lipoproteins, by reduction of HDL and of HDL-associated anti-oxidant enzyme activities.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
M. Moerland, H. Samyn, T. van Gent, R. van Haperen, G. Dallinga-Thie, F. Grosveld, A. van Tol, and R. de Crom
Acute Elevation of Plasma PLTP Activity Strongly Increases Pre-existing Atherosclerosis
Arterioscler. Thromb. Vasc. Biol., July 1, 2008; 28(7): 1277 - 1282.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
C. Minahk, K.-W. Kim, R. Nelson, B. Trigatti, R. Lehner, and D. E. Vance
Conversion of Low Density Lipoprotein-associated Phosphatidylcholine to Triacylglycerol by Primary Hepatocytes
J. Biol. Chem., March 7, 2008; 283(10): 6449 - 6458.
[Abstract] [Full Text] [PDF]


Home page
J. Lipid Res.Home page
M. Moerland, H. Samyn, T. van Gent, M. Jauhiainen, J. Metso, R. van Haperen, F. Grosveld, A. van Tol, and R. de Crom
Atherogenic, enlarged, and dysfunctional HDL in human PLTP/apoA-I double transgenic mice
J. Lipid Res., December 1, 2007; 48(12): 2622 - 2631.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
R. Liu, J. Iqbal, C. Yeang, D. Q.-H. Wang, M. M. Hussain, and X.-C. Jiang
Phospholipid Transfer Protein-Deficient Mice Absorb Less Cholesterol
Arterioscler. Thromb. Vasc. Biol., September 1, 2007; 27(9): 2014 - 2021.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
A. Wehinger, I. Tancevski, W. Schgoer, P. Eller, K. Hochegger, M. Morak, A. Hermetter, A. Ritsch, J. R. Patsch, and B. Foeger
Phospholipid Transfer Protein Augments Apoptosis in THP-1-Derived Macrophages Induced by Lipolyzed Hypertriglyceridemic Plasma
Arterioscler. Thromb. Vasc. Biol., April 1, 2007; 27(4): 908 - 915.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
R. Vikstedt, D. Ye, J. Metso, R. B. Hildebrand, T. J.C. Van Berkel, C. Ehnholm, M. Jauhiainen, and M. Van Eck
Macrophage Phospholipid Transfer Protein Contributes Significantly to Total Plasma Phospholipid Transfer Activity and Its Deficiency Leads to Diminished Atherosclerotic Lesion Development
Arterioscler. Thromb. Vasc. Biol., March 1, 2007; 27(3): 578 - 586.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
R. Liu, M. R. Hojjati, C. M. Devlin, I. H. Hansen, and X.-C. Jiang
Macrophage Phospholipid Transfer Protein Deficiency and ApoE Secretion: Impact on Mouse Plasma Cholesterol Levels and Atherosclerosis
Arterioscler. Thromb. Vasc. Biol., January 1, 2007; 27(1): 190 - 196.
[Abstract] [Full Text] [PDF]


Home page
J BiochemHome page
O. Zschenker, T. Illies, and D. Ameis
Overexpression of lysosomal Acid lipase and other proteins in atherosclerosis.
J. Biochem., July 1, 2006; 140(1): 23 - 38.
[Abstract] [Full Text] [PDF]


Home page
DiabetesHome page
G. M. Dallinga-Thie, A. van Tol, H. Hattori, P. C.N. Rensen, E. J.G. Sijbrands, and for the Diabetes Atorvastatin Lipid Intervention (
Plasma phospholipid transfer protein activity is decreased in type 2 diabetes during treatment with atorvastatin: a role for apolipoprotein e?
Diabetes, May 1, 2006; 55(5): 1491 - 1496.
[Abstract] [Full Text] [PDF]


Home page
J. Lipid Res.Home page
B. E. Aouizerat, M. B. Engler, Y. Natanzon, M. Kulkarni, J. Song, C. Eng, J. Huuskonen, C. Rivera, A. Poon, M. Bensley, et al.
Genetic variation of PLTP modulates lipoprotein profiles in hypoalphalipoproteinemia
J. Lipid Res., April 1, 2006; 47(4): 787 - 793.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
 All ASBMB Journals   Journal of Biological Chemistry 
 Molecular and Cellular Proteomics   ASBMB Today 
Copyright © 2004 by the American Society for Biochemistry and Molecular Biology.